Hypera Stock

Hypera EV/EBIT

The EV/EBIT (Enterprise Value to EBIT) of Hypera (HYPE3.SA) as of Aug 2, 2026 is 8.43. In the previous year, EV/EBIT (Enterprise Value to EBIT) was 8.40 — a change of 0.34% (higher).

EV/EBIT

8.43

YoY

0.34%

Last updated:

EV/EBIT (Enterprise Value to EBIT) of Hypera is 2026 8.43 . EV/EBIT (Enterprise Value to EBIT) of Hypera was 2025 8.40 . It decreases by 0.34% higher compared to the previous year.

The Hypera EV/EBIT history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

PRICE-TO-EBIT
Date
PRICE-TO-EBIT
Jan 1, 2019
21.44 base
Jan 1, 2020
15.42 base
Jan 1, 2021
8.83 base
Jan 1, 2022
11.13 base
Jan 1, 2023
9.84 base
Jan 1, 2024
6.00 base
Jan 1, 2025
7.40 base
Jan 1, 2026 (e)
4.90 base
YEARPRICE-TO-EBIT
2026 est 4.90
2025 7.40
2024 6.00
2023 9.84
2022 11.13
2021 8.83
2020 15.42
2019 21.44
2018 14.92
2017 19.51
2016 15.23
2015 15.45
2014 11.78
2013 12.01
2012 12.80
2011 13.73
2010 20.17
2009 20.72
2008 -
2007 -
2006 -
Access this data via the Eulerpool API
Get Free API Key

Hypera Valuation

Details

Historical Valuation Multiples

ⓘ

Price-to-Earnings Ratio (P/E)

The P/E ratio divides Hypera's share price by its earnings per share. It tells you how many years of current earnings you are "paying for" when you buy the stock. A P/E of 20 means you pay $20 for every $1 of annual earnings. The S&P 500 historically trades at an average P/E of roughly 15–17. A P/E significantly above that may signal high growth expectations; one below may indicate undervaluation — or declining business quality.

Price-to-Sales Ratio (P/S)

The P/S ratio divides market capitalization by total revenue. Unlike the P/E ratio, it works even for companies that are not yet profitable, making it essential for evaluating high-growth firms. A P/S below 1.0 may indicate undervaluation, while ratios above 10 are typically reserved for fast-growing tech or SaaS companies with high expected future margins.

Price-to-EBIT Ratio

This ratio relates Hypera's market price to its operating earnings, excluding the effects of debt structure and tax jurisdiction. It is particularly useful for comparing companies across different countries or with different levels of leverage, because it focuses purely on operational profitability. Lower values suggest cheaper operational earnings.

How to Use This Chart

This chart plots Hypera's valuation multiples over time. Compare the current P/E, P/S, and P/EBIT to their own historical averages — if the current ratio is well below the multi-year average, the stock may be relatively cheap compared to its own track record. Combine this with industry comparisons: a P/E that looks high in absolute terms may be justified if Hypera grows earnings faster than its peers.

Hypera Stock analysis

What does Hypera do? Hypera SA is a Brazilian pharmaceutical company founded in 2001, specializing in the development, production, and distribution of drugs, generics, medical devices, and cosmetic products primarily for the Brazilian healthcare industry. Hypera is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Hypera stock

EV/EBIT (Enterprise Value to EBIT) of Hypera is 8.43 in 2026.

Access this data via the Eulerpool API
Get Free API Key

Valuation — Hypera

P/EP/SEV/EBITP/BP/CFP/FCFPEGEV/RevenueEV/EBITDAEV/FCFEarnings YieldFCF YieldMarket capitalizationEnterprise ValueEV/EBITForward P/EP/TBVShareholder YieldBuyback YieldDiv.-Adj. PEGEV/OCF

All Key Metrics — Hypera